This cohort study evaluates the biofluid eMTBR-tau243 across a range of mixed 3-repeat and 4-repeat tauopathies, including Alzheimer disease, chronic traumatic encephalopathy, and frontotemporal lobar degeneration with MAPT.
This cohort study evaluates the biofluid eMTBR-tau243 across a range of mixed 3-repeat and 4-repeat tauopathies, including Alzheimer disease, chronic traumatic encephalopathy, and frontotemporal lobar degeneration with MAPT.